View in EDS

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.

Saved in:
Bibliographic Details
Title: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Authors: Lee MS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ryoo BY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Hsu CH; National Taiwan University Hospital, Taipei, Taiwan., Numata K; Yokohama City University Medical Center, Yokohama, Japan., Stein S; Yale School of Medicine, New Haven, CT, USA., Verret W; Genentech, South San Francisco, CA, USA., Hack SP; Genentech, South San Francisco, CA, USA., Spahn J; Genentech, South San Francisco, CA, USA., Liu B; Genentech, South San Francisco, CA, USA., Abdullah H; Genentech, South San Francisco, CA, USA., Wang Y; Genentech, South San Francisco, CA, USA., He AR; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Lee KH; Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kyunghunlee@snu.ac.kr.
Corporate Authors: GO30140 investigators
Source: The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 808-820.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32502443
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lee+MS%22">Lee MS</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Ryoo+BY%22">Ryoo BY</searchLink>; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Hsu+CH%22">Hsu CH</searchLink>; National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Numata+K%22">Numata K</searchLink>; Yokohama City University Medical Center, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Stein+S%22">Stein S</searchLink>; Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Verret+W%22">Verret W</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Spahn+J%22">Spahn J</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Liu+B%22">Liu B</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Abdullah+H%22">Abdullah H</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22He+AR%22">He AR</searchLink>; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Lee+KH%22">Lee KH</searchLink>; Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kyunghunlee@snu.ac.kr.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22GO30140+investigators%22">GO30140 investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 808-820.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32502443
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(20)30156-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 808
    Titles:
      – TitleFull: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lee MS
      – PersonEntity:
          Name:
            NameFull: Ryoo BY
      – PersonEntity:
          Name:
            NameFull: Hsu CH
      – PersonEntity:
          Name:
            NameFull: Numata K
      – PersonEntity:
          Name:
            NameFull: Stein S
      – PersonEntity:
          Name:
            NameFull: Verret W
      – PersonEntity:
          Name:
            NameFull: Hack SP
      – PersonEntity:
          Name:
            NameFull: Spahn J
      – PersonEntity:
          Name:
            NameFull: Liu B
      – PersonEntity:
          Name:
            NameFull: Abdullah H
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: He AR
      – PersonEntity:
          Name:
            NameFull: Lee KH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2020 Jun
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1